In bladder cancer, patients with EP300 mutations were associated with a positive prognosis and higher tumor mutational burden (TMB) scores, which was reported to be a biomarker for immunotherapy (Zhu et al. 2020). This evidence concerns the gene EP300 and urinary bladder carcinoma.